Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Executive Summary
Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working
You may also be interested in...
Trajenta’s German Renaissance Nipped In The Bud; Revised Dossier Falls Short
Comparator issues have wrecked reimbursement prospects for the second time for Boehringer/Lilly’s diabetes drug Trajenta in Germany as authorities dispute the utility of a study published in The Lancet comparing the product to the sulphonylurea glimepiride.
Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.
European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls
A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.